Is Rapid Cost-cutting The Answer To Merck’s R&D Woes?
This article was originally published in The Pink Sheet Daily
The Big Pharma has had plenty of problems with its pipeline in recent years but has taken steps to move the needle back in the right direction. For some analysts and investors that progress is not coming rapidly enough.
You may also be interested in...
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.